Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Invesco Galaxy Bitcoin ETF (BTCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Invesco Galaxy Bitcoin ETF — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Invesco Galaxy Bitcoin ETF trades at $62.6. Which is the better fit depends on your goals.
| ALNY | BTCO | |
|---|---|---|
Market Cap | $39.89B | — |
Sector | Health | Crypto-linked |
52-Week High | $491.22 | $125.14 |
52-Week Low | $278.09 | $58.40 |
Enterprise Value | $38.15B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
BTCO trades at $63.56, up 1.05% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. Key financial ratios including P/E, P/S, and ROE are unavailable, limiting fundamental assessment. The stock faces resistance near $64 and support at $61.
The outlook remains cautious due to weak technical momentum and lack of fundamental data. Risks include market volatility and competitive pressures. Investors should await earnings reports for clarity on profitability and growth prospects before considering a position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Invesco Galaxy Bitcoin ETF
BTCO is a spot Bitcoin ETF that tracks the price of Bitcoin directly. It offers investors a regulated and convenient way to gain exposure to the digital currency through a traditional brokerage account without holding the asset.
Read more on BTCO →
